港股异动 | 康方生物(09926)涨超5% 自研古莫奇单抗第二项适应症获NDA受理

Core Viewpoint - Kangfang Biopharma's new drug application for AK111, a humanized anti-IL-17A monoclonal antibody for treating active ankylosing spondylitis (AS), has been accepted by the National Medical Products Administration (NMPA) in China, potentially providing new treatment options for nearly 4 million AS patients in the country [1] Group 1 - Kangfang Biopharma's stock rose by 5.16%, reaching HKD 118.1, with a trading volume of HKD 231 million [1] - AK111 is the third major non-oncology product from Kangfang Biopharma to enter the market stage, following the successful launches of Inusimab (PCSK9) and Eruquimab (IL-12/IL-23) [1] - The acceptance of AK111's new drug application signifies the company's strengthening product portfolio and increasing competitiveness in the non-oncology sector [1] Group 2 - The company has successfully launched Inusimab and Eruquimab, both of which have been included in the national medical insurance catalog [1] - Other products like AK111 and Manduquimab are progressing towards commercialization, alongside the development of innovative drugs targeting multiple indications [1] - The ongoing development of drugs targeting IL-4R/ST2 and neurodegenerative diseases further enhances the company's product pipeline [1]